Bevacizumab-Based Therapies in the First-Line Treatment of Metastatic Colorectal Cancer Full Text
The Oncologist, Exclusive Author Commentary  Clinical Article

Strickler JH et al. – Bevacizumab has demonstrated efficacy in combination with a number of different backbone chemotherapy regimens, and its widespread use has introduced several important questions regarding the selection and optimization of bevacizumab–based treatment regimens, its use in various patient populations, and the identification of associated adverse events.

This review article addresses several controversies in the first line use of bevacizumab for metastatic colorectal cancer, and discusses recent research efforts to identify biomarkers of treatment sensitivity and resistance.

Please login or register to follow this author.
► Click here to access Full Text, PubMed, Publisher and related articles...
<< Previous Article | Next Article >>

    Currently, there are no available articles.

Your Unread Messages in Pharmacy

See All >> Messages include industry-sponsored communications and special communications from MDLinx

Most Popular Pharmacy Articles

Indexed Journals in Pharmacy: Expert Opinion in Pharmacotherapy, Formulary, U.S.Pharmacistmore